Kiniksa Q2 ARCALYST Revenue Jumps 55%, Guidance Raised to $980–$995M; Phase 3 Trial Underway
KNSA has more than doubled off its 52-week low of $26.27.
Summary
Kiniksa delivered a strong Q2 with ARCALYST net product revenue of $243.6M, up 55% year-over-year, and raised full-year guidance to $980–$995M. The growth reflects expanding prescriber adoption and longer treatment durations in recurrent pericarditis. The pipeline also advanced: KPL-387 Phase 2 data showed rapid pain and CRP normalization with once-monthly dosing, and the pivotal Phase 3 PASTORALE trial is now enrolling. A Phase 1 trial for KPL-1161, targeting quarterly dosing, is expected by year-end. This follows the May 8-K disclosing the Baker Bros. voting agreement, but today's results and pipeline progress are fresh catalysts. The raised guidance and Phase 3 initiation materially de-risk the growth story and next-generation pipeline.
At the time of this announcement, KNSA was trading at $63.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $26.27 to $67.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.